Neximmune Inc (NEXI)

$3.49

+0.19

(+5.76%)

Market is closed - opens 7 PM, 22 Apr 2024

Performance

  • $3.08
    $3.50
    $3.49
    downward going graph

    11.75%

    Downside

    Day's Volatility :12.0%

    Upside

    0.29%

    downward going graph
  • $1.25
    $28.69
    $3.49
    downward going graph

    64.18%

    Downside

    52 Weeks Volatility :95.64%

    Upside

    87.84%

    downward going graph

Returns

PeriodNeximmune Inc
3 Months
-38.34%
6 Months
-15.5%
1 Year
-63.49%
3 Years
-99.24%

Highlights

Market Capitalization
4.5M
Book Value
$7.8
Earnings Per Share (EPS)
-42.05
Wall Street Target Price
2.0
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-77.62%
Return On Equity TTM
-156.8%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-43.8M
Diluted Eps TTM
-42.05
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    75%Buy
    25%Hold
    0
    0%Sell
Based on 8 Wall street analysts offering stock ratings for Neximmune Inc(by analysts ranked 0 to 5 stars)
Based on 8 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Downside of 42.69%

Current $3.49
Target $2.00

Technicals Summary

Sell

Neutral

Buy

Neximmune Inc is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Neximmune Inc
Neximmune Inc
-38.99%
-15.5%
-63.49%
-99.24%
-99.45%
Moderna, Inc.
Moderna, Inc.
-1.62%
26.13%
-28.15%
-35.32%
329.16%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-7.25%
10.93%
12.37%
77.79%
168.48%
Novo Nordisk A/s
Novo Nordisk A/s
-5.87%
27.44%
48.41%
234.91%
410.23%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-4.33%
8.96%
19.79%
79.09%
133.97%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Neximmune Inc
Neximmune Inc
0.01
NA
NA
0.0
-1.57
-0.78
NA
7.8
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
25.72
25.72
1.46
45.22
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.32
46.32
2.4
3.33
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.33
28.33
0.53
16.77
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Neximmune Inc
Neximmune Inc
Buy
$4.5M
-99.45%
0.01
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$38.8B
329.16%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$98.1B
168.48%
25.72
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$550.4B
410.23%
46.32
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$101.7B
133.97%
28.33
36.68%

Institutional Holdings

  • Slate Path Capital LP

    2.84%
  • Adage Capital Partners Gp LLC

    2.46%
  • EPIQ Capital Group, LLC

    1.20%
  • PNC Financial Services Group Inc

    0.97%
  • Comerica Bank

    0.25%
  • Tower Research Capital LLC

    0.14%

Company Information

neximmune is an emerging biopharmaceutical company advancing a new generation of immunotherapies based on our proprietary aim™ technology. this nanotechnology platform, originally developed at johns hopkins university, is the foundation for an innovative approach to immunotherapy in which the body’s own immune system is stimulated to orchestrate a targeted t cell response against a disease. central to the aim technology are artificial antigen presenting cells (aapc) that present antigens to t cells eliciting a highly targeted therapy driven by the patient’s immune system. these aapc can be rapidly engineered to elicit a specific immune attack that can be directed toward any foreign substance or cell type in a patient’s body.

Organization
Neximmune Inc
Employees
22
CEO
Ms. Kristi Jones R.Ph.
Industry
Healthcare

FAQs